Compare Abrdn Physical Platinum Shares ETF (PPLT) vs Revvity Inc (RVTY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Abrdn Physical Platinum Shares ETF vs Revvity Inc — how do they compare? Abrdn Physical Platinum Shares ETF trades at $14.8, while Revvity Inc trades at $110.67 (market cap $12.33B). The key difference: Revvity Inc pays a 0.25% dividend while Abrdn Physical Platinum Shares ETF pays none, and Revvity Inc is trading nearer its 52-week high, Abrdn Physical Platinum Shares ETF nearer its low. Which is the better fit depends on your goals.
| PPLT | RVTY | |
|---|---|---|
Sector | Commodities - Metals/Agriculture | Technology |
52-Week High | $25.23 | $117.75 |
52-Week Low | $11.78 | $82.26 |
Market Cap | — | $12.33B |
Enterprise Value | — | $14.82B |
Dividend Yield | — | 0.25% |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
PPLT trades at $14.47, down 0.21% on the day, with a strong bearish technical signal from moving averages and a neutral stance from oscillators. The stock underwent a 1:10 forward split effective May 18, 2026. Recent news highlights platinum's underperformance versus gold and silver, with some analysts viewing the gap as a potential catch-up opportunity, while others caution after a significant rally.
The outlook is mixed; technicals suggest near-term pressure, but the valuation gap in precious metals could present a long-term opportunity. Key risks include commodity price volatility and the ETF's lack of dividend income. Investor sentiment is divided between those betting on a rebound and those taking profits after strong gains.
RVTY trades at $106.44, down 3.37% today, with a bullish technical outlook despite near-term weakness. The company maintains stable revenue around $2.9B with consistent earnings beats, though valuation multiples appear elevated with a P/E of 51. Recent AI product launches and FDA clearances demonstrate innovation in life sciences and diagnostics. Analyst consensus remains positive with a $111.43 price target and no sell ratings among 29 covering firms.
The stock presents a growth opportunity with strong analyst support and technological innovation, but faces risks from margin pressure and China market exposure. Current levels near support at $105 offer potential entry, though the high P/E requires sustained earnings growth to justify valuation. Upcoming Q2 earnings on August 4, 2026 will be critical for near-term direction.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Abrdn Physical Platinum Shares ETF
PPLT is a physically-backed ETF designed to track the spot price of platinum, less the Trust's expenses. It holds physical platinum bullion in secure vaults, providing investors with a liquid and cost-effective way to access the platinum market without the logistical challenges of direct ownership.
Read more on PPLT →About Revvity Inc
Revvity, Inc., formerly the Life Sciences and Diagnostics businesses of PerkinElmer, is a global provider of scientific and diagnostic solutions. The company focuses on the health and wellness of humanity through its expertise in life science research, detection, imaging, and informatics. Revvity supplies a broad portfolio of instruments, reagents, and services to pharmaceutical companies, academic research institutions, and clinical laboratories worldwide, enabling customers to make advancements in human health.
Read more on RVTY →
